Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1119-1125

  Yanni, Souzan B ^a   Annaert, Pieter P ^b   Augustijns, Patrick ^b   Bridges, Arlene ^a   Gao, Yan ^a   Benjamin Jr , Daniel K ^c   Thakker, Dhiren R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; VORICONAZOLE;

AEROBIC METABOLISM; ARTICLE; CATALYSIS; CONTROLLED STUDY; HEAT SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; OXIDATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; OXIDATION-REDUCTION; OXYGENASES; PYRIMIDINES; RECOMBINANT PROTEINS; TRIAZOLES;

FUNGI;

EID: 44149124304     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.019646     Document Type: Article

References (27)

1. Allerston CK, Shimizu M, Fujieda M, Shephard EA, Yamazaki H, and Phillips IR (2007) Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet Genomics 17:827-839.
2. Boucher HW, Groll AH, Chiou CC, and Walsh TJ (2004) Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drug 64:1997-2020.
3. Cashman JR (1995) Structural and catalytic properties of mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
4. Fisher MB, Yoon K, Vaughn ML, Strelevitz TJ, and Foti RS (2002) Flavin-containing monooxygenase activity in hepatocytes and microsomes: in vitro characterization and in vivo scaling of benzydamine clearance. Drug Metab Dispos 30:1087-1093.
5. Hines RN (2006) Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3. Expert Opin Drug Metab Toxicol 2:41-49.
6. Hyland R, Jones BC, and Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540-547.
7. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, and Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965-974.
8. Krueger SK and Williams DE (2005) Mammalian-flavin containing monooxygenase: structure/function, genetic polymorphism and role in drug metabolism. Pharmacol Ther 106:357-387.
9. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, and Romero A (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 42:395-402.
10. Luning U, Ross H, and Thondorf I (1998) Steric requirements of intraannular substituents in A,D-bridged calyx[6]arenes. J Chem Soc Perkin Trans 2:1313-1317.
11. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, and Haefeli WE (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 80:126-135.
12. Murayama N, Imai N, Nakane T, Shimizu M, and Yamazaki H (2007) Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 73:2020-2026.
13. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
14. Patterson TF (2002) Early use of antifungal therapy in high-risk patients. Curr Opin Infect Dis 15:561-563.
15. Purkins L, Wood N, Greenhalgh K, Allen MJ, and Oliver SD (2003a) Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 56 (Suppl 1):10-16.
16. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, and Nichols D (2003b) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 56:2-9.
17. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, and Kleinermans D (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553.
18. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, and Nichols D (2003c) No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 56:30-36.
19. Purkins L, Wood N, Kleinermans D, and Love ER (2003d) No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 56:62-68.
20. Rodriguez RJ, Proteau PJ, Marquez BL, Hetherington CL, Buckholz CJ, and O'Connell KL (1999) Flavin-containing monooxygenase-mediated metabolism of n-deacetyl ketoconazole by rat hepatic microsomes. Drug Metab Dispos 27:880-886.
21. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
22. Störmer E, Roots I, and Brockmoller J (2000) Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553-561.
23. Theuretzbacher U, Ihle F, and Derendorf H (2006) Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649-663.
24. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, et al. (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48:2166-2172.
25. Yanni SB, Thiel P, Haroldsen P, and Samara E (2004) High Throughput Evaluation of Clinical Drug Interaction using LCMSMS, ISSX Vancouver, Vancouver, BC, Canada.
26. Ziegler DM (1980) Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds. Enzymatic Basis Detox 1:201-217.
27. Ziegler DM (1993) Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 33:179-199.